Interestingly, miR-641 activates ERK signaling in NSCLC cells by directly targeting neurofibromatosis 1 (NF1), where NF1 overexpression or ERK silencing could block miR-641-induced NSCLC cell resistance to erlotinib treatment. This evidence concerns the gene NF1 and non-small cell lung carcinoma.